Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Enhanced Iontophoretic Delivery of Risedronate Sodium Across Hairless Mice Skin

무모생쥐 피부에 리제드로네이트 소디움의 이온토포레시스 경피전달

  • Hwang, In-Young (Department of Pharmaceutical Science) ;
  • Lee, Mi-Jung (Department of Pharmaceutical Science) ;
  • Jung, Suk-Hyun (Biomaterial Research Center, Korea Research Institute of Chemical Technology) ;
  • Jeong, Seo-Young (Department of Pharmaceutical Science) ;
  • Cho, Sun-Hang (Biomaterial Research Center, Korea Research Institute of Chemical Technology) ;
  • Gil, Young-Sig (R&D Center/Life Science Laboratory, Kolmar Korea CO., LTD) ;
  • Jeong, Sang-Young (R&D Center/Life Science Laboratory, Kolmar Korea CO., LTD) ;
  • Shin, Byung-Cheol (Biomaterial Research Center, Korea Research Institute of Chemical Technology)
  • 황인영 (경희대학교 약학대학 약제학실) ;
  • 이미정 (경희대학교 약학대학 약제학실) ;
  • 정석현 (한국화학연구원 바이오소재연구센터) ;
  • 정서영 (경희대학교 약학대학 약제학실) ;
  • 조선행 (한국화학연구원 바이오소재연구센터) ;
  • 길영식 ((주)한국콜마 생명과학연구소) ;
  • 정상영 ((주)한국콜마 생명과학연구소) ;
  • 신병철 (한국화학연구원 바이오소재연구센터)
  • Received : 2010.01.25
  • Accepted : 2010.02.17
  • Published : 2010.04.20
Download PDF
⟨ Previous Next ⟩

Abstract

Osteoporosis was traditionally defined by the occurrence of nontraumatic fractures, especially of the spine, in the setting of low bone mass. Bisphosphonates are an important group of therapeutic agents for the management of osteoporosis, as they inhibit bone resorption and increase bone density, thereby potentially decreasing fracture risk. Risedronate sodium is a bisphosphonate class used by oral formulation. In this study, risedronate was transdermally delivered by iontophoresis. Effects of polarity, pH, current density, and drug concentration were studied using a side-by-side diffusion cell including the hairless mice skin. In addition we studied effect of enhancers. The flux was evaluated by HPLC/UV system. The amount of transported drug under iontophoretic delivery was approximately 186 fold higher than that under passive delivery. Flux was proportional to the increase of drug concentration and current density. The flux was observed about 0.68mg/$cm^2$ when the amout of Propyleneglycol monolaurate (PGML) used 1% as enhancer. Results indicated that iontophoresis is an effective method for transdermal administration of risedronate sodium

Keywords

References

  1. F.S.J. Keating and J.C. Stevenson, Interventions for osteoporosis, Treatment of the postmenopausal Woman (Third Edition)., 351-375 (2007).
  2. R.M. Francis, Oral bisphosphonates in the treatment of osteoporosis, Curr. Ther. Res., 56, 831-851 (1995). https://doi.org/10.1016/0011-393X(95)85087-2
  3. H. Fleisch, Bisphosphonates mechanisms of action, Adv. Organ. Biol., 5, 835-850 (1998). https://doi.org/10.1016/S1569-2590(08)60154-8
  4. P.T. Vallano, S.B. Shugarts, W.F. Kline, E.J. Woolf and B.K. Matuszewski, Determination of risedronate in human urine by column-switching ion-pair high-performance liquid chromatography with ultraviolet detection, J. Chromatogr. B., 794, 23-33 (2003). https://doi.org/10.1016/S1570-0232(03)00394-5
  5. H.J. Jia, W. Li and K. Zhao, Determination of risedronate in rat plasma samples by ion-pair high-performance liquid chromatography with UV detector, Anal. Chim. Acta., 562, 171-175 (2006). https://doi.org/10.1016/j.aca.2006.01.077
  6. T. Tanvetyanon and P.J. Stiff, Managment of the adverse effects associated with intravenous bisphosphonates, Anals of Oncology., 17, 897-907 (2006). https://doi.org/10.1093/annonc/mdj105
  7. M.J. Pikal, The role of electroosmotic flow in transdermal iontophoresis, Adv. Drug. Deliv. Rev., 46, 281-305 (2001). https://doi.org/10.1016/S0169-409X(00)00138-1
  8. A.C. Willinams and B.W. Barry, Skin absorption enhancers, Crit. Rev. Ther. Drug. Carrier. Syst., 9, 305-353 (1992).
  9. T.K. Ghosh and W.R. Pfister, Transdermal and topical drug delivery systems, Interpharm press., 345-346 (1997).
  10. K. Karami and P. Beronius, On iontophoretic delivery enhancement. Ionization and mobility of lidocaine hydrochloride in propylene glycol, Int J. Pharm., 168, 85-95 (1998). https://doi.org/10.1016/S0378-5173(98)00090-8
  11. R.H. Guy, Y.N. Kalia. V. Merino, A. Lopez and D. Marro, Iontophoresis : electrorepulsion and electroosmosis, J. Controlled Release., 64, 129-132 (2000). https://doi.org/10.1016/S0168-3659(99)00132-7
  12. K. Katayama, R. Matsui, T. Hatanaka and T. Koizumi, Effect of pH on skin permeation enhancement of acidic drugs by 1-menthol-ethanol system, Int. J. Pharm., 226, 69-80 (2001). https://doi.org/10.1016/S0378-5173(01)00778-5
  13. J. Singh, M. Gross, B. Sage, H.T. Davis and H.I. Maibach, Regional variations in skin barrier function and cutaneous irritation due to iontophoresis in human subjects, Food. Chem. Toxicol., 39, 1079-1086 (2001) https://doi.org/10.1016/S0278-6915(01)00057-6
  14. T.K. Ghosh and W.R. Pfister, Transdermal and topical drug delivery systems, Interpharm press., 372-423 (1997).
  15. K. Sugibayashi, K. Nakayama, T. Seki, K. Hosoya and Y. Morimoto, Mechanism of skin penetration-enhancing effect by laurocapram, J. Pharm. Sci., 81, 58-64 (1992). https://doi.org/10.1002/jps.2600810112
  16. S.D. Roy, E. Roos and K. Sharma, Transdermal delivery of buprenorphine throught cadaver skin, J. Pharm. Sci., 83, 126-30 (1994). https://doi.org/10.1002/jps.2600830204
  17. H.S. Gwak, and I.K. Chun, effect of vehicles and penetration enhancer on the in vitro percutaneous absorption of tenoxicam through hairless mouse skin, Int. J. Pharm., 236, 57-64 (2002). https://doi.org/10.1016/S0378-5173(02)00009-1
  18. C. Ramachandran and D. Fleisher, Transdermal delivery of drug for the treatment of bone diseases, Adv. Drug. Deliv. Rev., 42, 197-223 (2000). https://doi.org/10.1016/S0169-409X(00)00062-4